The rise of the work drug Elon Musk is taking ketamine and techies are microdosing mushrooms. So it's OK to do drugs at work now?


Elon Musk has sparked controversy with his alleged use of drugs. While initially denying such claims, he has now shifted his stance, acknowledging the use of ketamine for depression and even suggesting that it could be beneficial for shareholders if his companies are thriving. This shift in perspective reflects a larger trend where professionals are turning to substances like LSD, psilocybin, and ketamine to enhance their performance.

Microdosing, a practice where individuals consume small amounts of these drugs, has gained popularity among various groups, including working professionals and moms. Anecdotal evidence suggests that it can improve creativity, focus, and overall well-being, but the scientific community remains uncertain about its actual efficacy.

The precise dosing of these drugs poses a challenge, as slight variations in the amount consumed can lead to unintended perceptual experiences. Moreover, some corporate leaders are exploring macrodosing through luxury psychedelic retreats, aiming to transform their leadership skills and perceptions. However, the outcomes of such experiences are difficult to predict, and the pressure on team members to participate in these activities raises ethical concerns.

While the integration of psychedelic experiences into the corporate world presents potential benefits, it also carries significant risks. The legal and health implications of using these substances, as well as potential workplace pressures, need to be carefully considered. Despite the allure of enhanced performance and the growing market for psychedelics, the complex nature of these substances calls for a balanced assessment of their impact on professional life.  

Post a Comment

Previous Post Next Post